The overall goal of this proposal is to develop effective chemopreventive strategies and understand the molecular mechanism of colon tumor inhibition by a combination of statins (3- hydroxy-3methyl glutaryl CoA reductase (HMG-R) inhibitors) and polyamine inhibitor, DFMO against colon cancer. Colorectal cancer is one of the most common malignancies in both men and women in the US. In developing translational strategies, a preferable approach is to target multiple signaling pathways that selectively contribute towards tumor growth, so that it provides a synergistic/additive efficacy. Colon tumor cells produce high levels of polyamines endogenously through the activation of ornithine decarboxylase (ODC). DFMO selectively inhibits ODC activity and thereby endogenous polyamine synthesis and colon tumor growth. New insights into the transport of polyamines in tumor cells by caveolin-1 (cav-1) and SLC3A2 mediated pathways suggest that new approaches are needed for effective polyamine regulation in tumor cells. In spite of the fact that DFMO inhibits endogenous polyamine synthesis, tumor cells can still uptake extracellular polyamines through a cav-1 dependent endocytic mechanism. Further, Cav-1 plays an important role in the generation of nitric oxide (NO) and activation of AKT and Rho-signaling, leading to enhanced tumor cell proliferation and invasion. Our preliminary results suggest, that a combination of rosuvastatin with low-dose DFMO suppresses azoxymethane (AOM)-induced colonic aberrant crypt foci (ACF), and aberrant crypt cell proliferation. Our in vitro and in vivo results suggest that cav-1 plays an important role in colon cancer, and statins exhibit colon tumor inhibition in part by modulating cav-1. Therefore, we want to develop a combination of statin and DFMO for colon cancer prevention/treatment and understand the role of cav-1 in colon cancer and its possible regulation by miRNAs.
Specific aims are 1) Determine the in vivo efficacy of Rosuvastatin (Crestor) in a F344 rat colon carcinogenesis model (maximum tolerated/optimal dose selection;dose- response effects;and effectiveness during promotion/progression stages (early/late interventions). 2) Determine the combinational efficacy of atorvastatin/rosuvastatin and DFMO on the progression of colonic ACF (post-initiation/early stage) or adenoma (progression/late stage) to colon adenocarcinoma formation in rats. We also want to determine the effect of statins and DFMO on the levels of cav-1, polyamines, ODC activity, NO (iNOS and eNOS activities), SLC3A2, AKT and Rho signaling proteins, miRNA modifications in colonic mucosa and tumor tissues and correlate these results with colon tumor inhibition. 3) Define the role of cav-1 in colon carcinogenesis using cav-1-/- knockout mouse model and determine the effect of statins with or without DFMO on carcinogen induced colon tumor formation in cav- 1-/- and cav-1+/+ mice. In addition, proposed research will elucidate the role of selective miRNAs on the regulation of cav-1 in colon cancer cells, and assess the possible modulatory role of statins and DFMO on cav-1 miRNA regulation.

Public Health Relevance

Colorectal cancer is one of the most common malignancies in both men and women in the US accounting for 50,000 deaths annually. Developing translational strategies to prevent the malignant progression of colon tumor growth is an ideal approach. The proposed studies will produce a detailed preclinical evaluation, thus setting the stage for the eventual clinical assessment of statins either alone or in combination with low-dose ODC inhibitor for colon cancer prevention and treatment. In addition, these studies will also provide valuable information on the most widely used statin, rosuvastatin which exerts multiple health benefits in humans and especially for colon cancer prevention, when it is specifically administered during the adenoma stage of colon carcinogenesis. Furthermore, the proposed studies will provide mechanistic insight into how a combination of statins and ODC inhibitors provides enhanced suppression of cellular polyamine levels leading to synergistic colon tumor growth inhibition and finally elucidate the role of cav-1 in colon cancer/prevention.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Chemo/Dietary Prevention Study Section (CDP)
Program Officer
Malone, Winfred F
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Oklahoma Health Sciences Center
Internal Medicine/Medicine
Schools of Medicine
Oklahoma City
United States
Zip Code
Pathuri, Gopal; Li, Qian; Mohammed, Altaf et al. (2014) Synthesis and in vivo evaluation of N-ethylamino-2-oxo-1,2-dihydro-quinoline-3-carboxamide for inhibition of intestinal tumorigenesis in APC(Min/+) mice. Bioorg Med Chem Lett 24:1380-2
Madka, Venkateshwar; Rao, Chinthalapally V (2013) Anti-inflammatory phytochemicals for chemoprevention of colon cancer. Curr Cancer Drug Targets 13:542-57
Suh, Nanjoo; Reddy, Bandaru S; DeCastro, Andrew et al. (2011) Combination of atorvastatin with sulindac or naproxen profoundly inhibits colonic adenocarcinomas by suppressing the p65/?-catenin/cyclin D1 signaling pathway in rats. Cancer Prev Res (Phila) 4:1895-902
Janakiram, Naveena B; Mohammed, Altaf; Rao, Chinthalapally V (2011) Role of lipoxins, resolvins, and other bioactive lipids in colon and pancreatic cancer. Cancer Metastasis Rev 30:507-23
Rao, Chinthalapally V; Steele, Vernon E; Swamy, Malisetty V et al. (2009) Inhibition of azoxymethane-induced colorectal cancer by CP-31398, a TP53 modulator, alone or in combination with low doses of celecoxib in male F344 rats. Cancer Res 69:8175-82
Janakiram, Naveena B; Rao, Chinthalapally V (2009) Role of lipoxins and resolvins as anti-inflammatory and proresolving mediators in colon cancer. Curr Mol Med 9:565-79
Guruswamy, Suresh; Rao, Chinthalapally V (2009) Synergistic effects of lovastatin and celecoxib on caveolin-1 and its down-stream signaling molecules: Implications for colon cancer prevention. Int J Oncol 35:1037-43
Janakiram, Naveena B; Steele, Vernon E; Rao, Chinthalapally V (2009) Estrogen receptor-beta as a potential target for colon cancer prevention: chemoprevention of azoxymethane-induced colon carcinogenesis by raloxifene in F344 rats. Cancer Prev Res (Phila Pa) 2:52-9
Rao, Chinthalapally V; Swamy, Malisetty V; Patlolla, Jagan M R et al. (2008) Suppression of familial adenomatous polyposis by CP-31398, a TP53 modulator, in APCmin/+ mice. Cancer Res 68:7670-5
Guruswamy, Suresh; Rao, Chinthalapally V (2008) Multi-Target Approaches in Colon Cancer Chemoprevention Based on Systems Biology of Tumor Cell-Signaling. Gene Regul Syst Bio 2:163-176

Showing the most recent 10 out of 22 publications